FANCI
MCID: FNC029
MIFTS: 50

Fanconi Anemia, Complementation Group I (FANCI)

Categories: Blood diseases, Bone diseases, Cancer diseases, Fetal diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Fanconi Anemia, Complementation Group I

MalaCards integrated aliases for Fanconi Anemia, Complementation Group I:

Name: Fanconi Anemia, Complementation Group I 56 29 13 6 39 71
Fanconi Anemia Complementation Group I 12 73 15
Fanci 56 12 73

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
fanconi anemia, complementation group i:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Fanconi Anemia, Complementation Group I

OMIM : 56 Fanconi anemia (FA) is a clinically and genetically heterogeneous disorder that causes genomic instability. Characteristic clinical features include developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. The cellular hallmark of FA is hypersensitivity to DNA crosslinking agents and high frequency of chromosomal aberrations pointing to a defect in DNA repair (summary by Deakyne and Mazin, 2011). For additional general information and a discussion of genetic heterogeneity of Fanconi anemia, see 227650. (609053)

MalaCards based summary : Fanconi Anemia, Complementation Group I, also known as fanconi anemia complementation group i, is related to fanconi anemia, complementation group l and fanconi anemia, complementation group d2. An important gene associated with Fanconi Anemia, Complementation Group I is FANCI (FA Complementation Group I), and among its related pathways/superpathways are DNA Double-Strand Break Repair and DNA Damage. Affiliated tissues include bone, bone marrow and heart, and related phenotypes are abnormality of cardiovascular system morphology and abnormal renal morphology

Disease Ontology : 12 A Fanconi anemia that has material basis in homozygous or compound heterozygous mutation in the FANCI gene on chromosome 15q26.

UniProtKB/Swiss-Prot : 73 Fanconi anemia complementation group I: A disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair.

Related Diseases for Fanconi Anemia, Complementation Group I

Diseases in the Fanconi Anemia, Complementation Group C family:

Fanconi Anemia, Complementation Group D2 Fanconi Anemia, Complementation Group a
Fanconi Anemia, Complementation Group B Fanconi Anemia, Complementation Group E
Fanconi Anemia, Complementation Group F Fanconi Anemia, Complementation Group D1
Fanconi Anemia, Complementation Group I Fanconi Anemia, Complementation Group J
Fanconi Anemia, Complementation Group N Fanconi Anemia, Complementation Group O
Fanconi Anemia, Complementation Group P Fanconi Anemia, Complementation Group G
Fanconi Anemia, Complementation Group L Fanconi Anemia, Complementation Group Q
Fanconi Anemia, Complementation Group T Fanconi Anemia, Complementation Group V
Fanconi Anemia, Complementation Group R Fanconi Anemia, Complementation Group U
Fanconi Anemia, Complementation Group W Fanconi Anemia, Complementation Group S

Diseases related to Fanconi Anemia, Complementation Group I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 fanconi anemia, complementation group l 32.5 FANCI FANCD2
2 fanconi anemia, complementation group d2 32.3 H2AC18 FANCI FANCD2
3 thrombophlebitis migrans 32.0 POLG FANCI
4 mitochondrial dna depletion syndrome 4b 32.0 POLG FANCI
5 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 31.9 POLG FANCI
6 mitochondrial dna depletion syndrome 1 31.9 POLG FANCI
7 autosomal dominant progressive external ophthalmoplegia 31.9 POLG FANCI
8 fanconi anemia, complementation group c 31.8 FANCI FANCD2
9 fanconi anemia, complementation group t 31.7 H2AC18 FANCM FANCI FANCD2
10 fanconi anemia, complementation group d1 31.7 H2AC18 FANCM FANCI FANCD2
11 esophageal atresia 31.7 FANCM FANCI FANCD2
12 fanconi anemia, complementation group j 31.7 H2AC18 FANCM FANCI FANCD2
13 fanconi anemia, complementation group n 31.7 H2AC18 FANCM FANCI FANCD2
14 interstitial nephritis, karyomegalic 31.6 FANCI FANCD2 FAN1
15 fanconi anemia, complementation group u 31.6 FANCM FANCI FANCD2
16 fanconi anemia, complementation group v 31.5 FANCM FANCI FANCD2
17 fanconi anemia, complementation group r 31.5 FANCM FANCI FANCD2
18 fanconi anemia, complementation group q 31.5 FANCM FANCI FANCD2
19 fanconi anemia, complementation group o 31.5 FANCM FANCI FANCD2
20 fanconi anemia, complementation group p 31.2 H2AC18 FANCM FANCI FANCD2
21 aplastic anemia 31.1 H2AC18 FANCM FANCI FANCD2
22 congenital hypoplastic anemia 30.8 USP1 H2AC18 FANCM FANCI FANCD2
23 seckel syndrome 30.7 H2AC18 FANCM FANCI FANCD2 ATR
24 xeroderma pigmentosum, variant type 30.6 USP1 H2AC18 FANCM FANCI FANCD2 ATR
25 fanconi anemia, complementation group a 28.5 USP1 H2AC18 FANCM FANCI FANCD2 FAN1
26 vacterl association 11.5
27 cervical squamous cell carcinoma 11.0
28 hepatosplenic t-cell lymphoma 11.0
29 fanconi anemia, complementation group f 10.2 H2AC18 FANCD2
30 heart disease 10.1
31 bronchitis 10.1
32 peptic ulcer disease 10.1
33 deficiency anemia 10.1
34 aging 10.0
35 vascular disease 10.0
36 dermatitis 10.0
37 ischemia 10.0
38 adenoma 10.0
39 pyruvate dehydrogenase e1-alpha deficiency 10.0 POLG H2AC18
40 xeroderma pigmentosum, complementation group f 10.0 FANCM FANCD2
41 neurofibromatosis, type ii 10.0
42 atherosclerosis susceptibility 10.0
43 coronary heart disease 1 10.0
44 endometrial cancer 10.0
45 myocardial infarction 10.0
46 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
47 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.0
48 hydrops, lactic acidosis, and sideroblastic anemia 10.0
49 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.0
50 exanthem 10.0

Graphical network of the top 20 diseases related to Fanconi Anemia, Complementation Group I:



Diseases related to Fanconi Anemia, Complementation Group I

Symptoms & Phenotypes for Fanconi Anemia, Complementation Group I

Human phenotypes related to Fanconi Anemia, Complementation Group I:

31 (show all 34)
# Description HPO Frequency HPO Source Accession
1 abnormality of cardiovascular system morphology 31 occasional (7.5%) HP:0030680
2 abnormal renal morphology 31 occasional (7.5%) HP:0012210
3 short stature 31 very rare (1%) HP:0004322
4 bone marrow hypocellularity 31 very rare (1%) HP:0005528
5 chromosomal breakage induced by crosslinking agents 31 very rare (1%) HP:0003221
6 short neck 31 HP:0000470
7 agenesis of corpus callosum 31 HP:0001274
8 hypothyroidism 31 HP:0000821
9 global developmental delay 31 HP:0001263
10 horseshoe kidney 31 HP:0000085
11 cafe-au-lait spot 31 HP:0000957
12 intrauterine growth retardation 31 HP:0001511
13 ventricular septal defect 31 HP:0001629
14 microcephaly 31 HP:0000252
15 pallor 31 HP:0000980
16 myopia 31 HP:0000545
17 optic nerve hypoplasia 31 HP:0000609
18 microphthalmia 31 HP:0000568
19 vesicoureteral reflux 31 HP:0000076
20 patent foramen ovale 31 HP:0001655
21 neutropenia 31 HP:0001875
22 arnold-chiari malformation 31 HP:0002308
23 conductive hearing impairment 31 HP:0000405
24 renal hypoplasia 31 HP:0000089
25 growth hormone deficiency 31 HP:0000824
26 absent septum pellucidum 31 HP:0001331
27 triangular face 31 HP:0000325
28 decreased body weight 31 HP:0004325
29 astigmatism 31 HP:0000483
30 short 1st metacarpal 31 HP:0010034
31 hypoplasia of the radius 31 HP:0002984
32 colpocephaly 31 HP:0030048
33 fused cervical vertebrae 31 HP:0002949
34 absent thumb 31 HP:0009777

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Neck:
short neck

Endocrine Features:
hypothyroidism
growth hormone deficiency
hypothyroidism, tertiary (central)

Genitourinary Kidneys:
horseshoe kidney
hypoplastic kidneys

Head And Neck Head:
microcephaly

Genitourinary Ureters:
vesicoureteral reflux

Head And Neck Face:
triangular face
fanconi facies

Head And Neck Ears:
hearing loss, conductive
right auditory canal atresia
auditory canal stenosis
abnormal ossicles

Growth Weight:
low weight

Skeletal Limbs:
short radius

Abdomen Gastrointestinal:
duodenum atresia

Neurologic Central Nervous System:
agenesis of corpus callosum
arnold-chiari malformation
absent septum pellucidum
colpocephaly
developmental delay
more
Growth Height:
short stature

Cardiovascular Heart:
ventricular septal defect
atrial septal defect
patent foramen ovale

Head And Neck Eyes:
myopia
optic nerve hypoplasia
microphthalmia
astigmatism
optic nerve pallor

Hematology:
neutropenia

Skeletal Spine:
fused cervical vertebrae
narrow c5 vertebra

Skeletal Hands:
absent thumbs
short first metacarpal
hypoplastic thumb
dangling left thumb

Skin Nails Hair Skin:
cafe-au-lait spots

Growth Other:
intrauterine growth retardation (iugr)
small for gestation age (<10%)

Clinical features from OMIM:

609053

GenomeRNAi Phenotypes related to Fanconi Anemia, Complementation Group I according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 AIMP2 ATR BAG2 FAN1 FANCD2 FANCM
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 AIMP2 ATR BAG2 FAN1 FANCD2 FANCM
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATR FAN1 FANCD2 FANCI FANCM USP1

Drugs & Therapeutics for Fanconi Anemia, Complementation Group I

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Acute Neurobehavioral Program for Improving Functional Status After TBI Unknown status NCT01166386 Phase 3
2 A Study on the Homologous Recombination Deficiency Status in Chinese Population With Epithelial Ovarian Cancer Recruiting NCT04190667

Search NIH Clinical Center for Fanconi Anemia, Complementation Group I

Genetic Tests for Fanconi Anemia, Complementation Group I

Genetic tests related to Fanconi Anemia, Complementation Group I:

# Genetic test Affiliating Genes
1 Fanconi Anemia, Complementation Group I 29 FANCI

Anatomical Context for Fanconi Anemia, Complementation Group I

MalaCards organs/tissues related to Fanconi Anemia, Complementation Group I:

40
Bone, Bone Marrow, Heart, Breast, Kidney, T Cells, Lung

Publications for Fanconi Anemia, Complementation Group I

Articles related to Fanconi Anemia, Complementation Group I:

(show top 50) (show all 200)
# Title Authors PMID Year
1
FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. 61 56 6
17460694 2007
2
Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. 61 56 6
17412408 2007
3
Identification of the Fanconi anemia complementation group I gene, FANCI. 61 56 6
17452773 2007
4
Novel FANCI mutations in Fanconi anemia with VACTERL association. 61 56
26590883 2016
5
Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. 61 56
14630800 2004
6
Fanconi anemia: at the crossroads of DNA repair. 56
21568838 2011
7
ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. 6
19888064 2009
8
Esophageal Atresia/Tracheoesophageal Fistula Overview 6
20301753 2009
9
Carrier screening in individuals of Ashkenazi Jewish descent. 6
18197057 2008
10
Fanconi Anemia 6
20301575 2002
11
In vivo analysis of FANCD2 recruitment at meiotic DNA breaks in Caenorhabditis elegans. 61
31919410 2020
12
MLH1-mediated recruitment of FAN1 to chromatin for the induction of apoptosis triggered by O6 -methylguanine. 61
31955481 2020
13
FANCI Cooperates with IMPDH2 to Promote Lung Adenocarcinoma Tumor Growth via a MEK/ERK/MMPs Pathway. 61
32021289 2020
14
Allosteric mechanism for site-specific ubiquitination of FANCD2. 61
31873223 2019
15
Structure of the Fanconi anaemia monoubiquitin ligase complex. 61
31666700 2019
16
MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy. 61
31477281 2019
17
Small-Molecule Inhibition of UBE2T/FANCL-Mediated Ubiquitylation in the Fanconi Anemia Pathway. 61
31525021 2019
18
Revisiting the Genomic and Transcriptomic Landscapes from Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine. 61
31783305 2019
19
Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. 61
30293905 2019
20
FANCD2 Binding to H4K20me2 via a Methyl-Binding Domain Is Essential for Efficient DNA Cross-Link Repair. 61
31085681 2019
21
A Fanci knockout mouse model reveals common and distinct functions for FANCI and FANCD2. 61
31219578 2019
22
Phosphorylation of FANCD2 Inhibits the FANCD2/FANCI Complex and Suppresses the Fanconi Anemia Pathway in the Absence of DNA Damage. 61
31167143 2019
23
USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy. 61
30335599 2019
24
Deficiency of the Fanconi anemia E2 ubiqitin conjugase UBE2T only partially abrogates Alu-mediated recombination in a new model of homology dependent recombination. 61
30715513 2019
25
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. 61
30303537 2019
26
Genetic characterization of thymoma. 61
30787364 2019
27
Fanconi anemia protein FANCI functions in ribosome biogenesis. 61
30692263 2019
28
High-risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de-ubiquitination of FancD2. 61
30818369 2019
29
FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat. 61
30358836 2019
30
Identification of significant gene and pathways involved in HBV-related hepatocellular carcinoma by bioinformatics analysis. 61
31392101 2019
31
Enzymatic preparation of monoubiquitinated FANCD2 and FANCI proteins. 61
30850063 2019
32
Binding of FANCI-FANCD2 Complex to RNA and R-Loops Stimulates Robust FANCD2 Monoubiquitination. 61
30650351 2019
33
Mutation Spectrum of Cancer-Associated Genes in Patients With Early Onset of Colorectal Cancer. 61
31428572 2019
34
BRMS1 participates in regulating cell sensitivity to DNA interstrand crosslink damage by interacting with FANCI. 61
30365131 2019
35
The Interplay Between the DNA Damage Response, RNA Processing and Extracellular Vesicles. 61
32010626 2019
36
CTDP1 regulates breast cancer survival and DNA repair through BRCT-specific interactions with FANCI. 61
31240132 2019
37
Integration of Gene Expression Profile Data to Verify Hub Genes of Patients with Stanford A Aortic Dissection. 61
31380418 2019
38
Integrative analysis with expanded DNA methylation data reveals common key regulators and pathways in cancers. 61
30729033 2019
39
Multiplexed CRISPR/Cas9-mediated knockout of 19 Fanconi anemia pathway genes in zebrafish revealed their roles in growth, sexual development and fertility. 61
30540754 2018
40
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. 61
30306255 2018
41
Specificity for deubiquitination of monoubiquitinated FANCD2 is driven by the N-terminus of USP1. 61
30456385 2018
42
The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. 61
29295643 2018
43
Effects of Sepantronium Bromide (YM-155) on the Whole Transcriptome of MDA-MB-231 Cells: Highlight on Impaired ATR/ATM Fanconi Anemia DNA Damage Response. 61
29976630 2018
44
The concerted roles of FANCM and Rad52 in the protection of common fragile sites. 61
30022024 2018
45
Replication Fork Reversal during DNA Interstrand Crosslink Repair Requires CMG Unloading. 61
29924986 2018
46
Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48. 61
29891926 2018
47
Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. 61
29659569 2018
48
Structural mechanism of DNA interstrand cross-link unhooking by the bacterial FAN1 nuclease. 61
29514982 2018
49
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers. 61
29452344 2018
50
Fanconi anaemia and cancer: an intricate relationship. 61
29376519 2018

Variations for Fanconi Anemia, Complementation Group I

ClinVar genetic disease variations for Fanconi Anemia, Complementation Group I:

6 (show all 25) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FANCI FANCI, 2T-CSNV Pathogenic 971
2 FANCI NM_018193.3(FANCI):c.3674G>A (p.Arg1225Gln)SNV Pathogenic 972 rs121918163 15:89858550-89858550 15:89315319-89315319
3 FANCI FANCI, IVS31AS, A-G, -88SNV Pathogenic 974
4 FANCI NM_001113378.1(FANCI):c.1461T>A (p.Tyr487Ter)SNV Pathogenic 408247 rs769248873 15:89824480-89824480 15:89281249-89281249
5 FANCI NM_001113378.1(FANCI):c.2422A>T (p.Lys808Ter)SNV Pathogenic/Likely pathogenic 208639 rs375656231 15:89837194-89837194 15:89293963-89293963
6 FANCI NM_001113378.1(FANCI):c.158-2A>GSNV Likely pathogenic 225355 rs762128147 15:89803942-89803942 15:89260711-89260711
7 FANCI NM_001113378.1(FANCI):c.2509G>T (p.Glu837Ter)SNV Likely pathogenic 631743 rs748000458 15:89838198-89838198 15:89294967-89294967
8 FANCI NM_001113378.1(FANCI):c.3041G>A (p.Cys1014Tyr)SNV Likely pathogenic 631744 rs140404896 15:89847129-89847129 15:89303898-89303898
9 FANCI NM_018193.3(FANCI):c.3673C>T (p.Arg1225Ter)SNV Uncertain significance 973 rs121918164 15:89858549-89858549 15:89315318-89315318
10 FANCI NM_001113378.1(FANCI):c.1399G>A (p.Val467Ile)SNV Uncertain significance 238308 rs199726965 15:89824418-89824418 15:89281187-89281187
11 FANCI NM_001113378.1(FANCI):c.467G>A (p.Cys156Tyr)SNV Uncertain significance 317261 rs112387610 15:89805073-89805073 15:89261842-89261842
12 FANCI NM_001113378.1(FANCI):c.849T>A (p.Tyr283Ter)SNV Uncertain significance 317266 rs760412752 15:89811723-89811723 15:89268492-89268492
13 FANCI NM_001113378.1(FANCI):c.1412C>G (p.Pro471Arg)SNV Uncertain significance 408243 rs139072231 15:89824431-89824431 15:89281200-89281200
14 FANCI NM_001113378.1(FANCI):c.2960C>T (p.Thr987Met)SNV Uncertain significance 408238 rs138432305 15:89844627-89844627 15:89301396-89301396
15 FANCI NM_002693.2(POLG):c.*333C>TSNV Uncertain significance 408231 rs369058619 15:89859649-89859649 15:89316418-89316418
16 FANCI NM_001113378.1(FANCI):c.2434A>G (p.Ser812Gly)SNV Uncertain significance 408252 rs768500794 15:89837206-89837206 15:89293975-89293975
17 FANCI NM_001113378.1(FANCI):c.1850C>G (p.Ser617Cys)SNV Uncertain significance 456198 rs749295501 15:89833472-89833472 15:89290241-89290241
18 FANCI NM_001113378.1(FANCI):c.2203A>G (p.Ile735Val)SNV Uncertain significance 456205 rs377308647 15:89836206-89836206 15:89292975-89292975
19 FANCI NM_001113378.1(FANCI):c.2992C>T (p.Pro998Ser)SNV Uncertain significance 526330 rs182154506 15:89844659-89844659 15:89301428-89301428
20 FANCI NM_001113378.1(FANCI):c.2071G>A (p.Glu691Lys)SNV Uncertain significance 571747 rs144419129 15:89835997-89835997 15:89292766-89292766
21 FANCI NM_001113378.1(FANCI):c.2614C>G (p.Gln872Glu)SNV Uncertain significance 576117 rs1368909419 15:89838303-89838303 15:89295072-89295072
22 FANCI NM_001113378.1(FANCI):c.3499T>G (p.Cys1167Gly)SNV Uncertain significance 581189 rs61744917 15:89849387-89849387 15:89306156-89306156
23 FANCI NM_001113378.1(FANCI):c.919C>T (p.Pro307Ser)SNV Uncertain significance 575021 rs769485443 15:89816644-89816644 15:89273413-89273413
24 FANCI NM_018193.3(FANCI):c.1743A>C (p.Glu581Asp)SNV Uncertain significance 625939 rs779310267 15:89828371-89828371 15:89285140-89285140
25 FANCI NM_018193.3(FANCI):c.557T>C (p.Leu186Pro)SNV Uncertain significance 625938 rs1370113722 15:89807145-89807145 15:89263914-89263914

UniProtKB/Swiss-Prot genetic disease variations for Fanconi Anemia, Complementation Group I:

73
# Symbol AA change Variation ID SNP ID
1 FANCI p.His858Tyr VAR_032691
2 FANCI p.Arg1285Gln VAR_032692 rs121918163

Expression for Fanconi Anemia, Complementation Group I

Search GEO for disease gene expression data for Fanconi Anemia, Complementation Group I.

Pathways for Fanconi Anemia, Complementation Group I

GO Terms for Fanconi Anemia, Complementation Group I

Biological processes related to Fanconi Anemia, Complementation Group I according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.63 USP1 FANCM FANCI FANCD2 FAN1 ATR
2 nucleic acid phosphodiester bond hydrolysis GO:0090305 9.43 POLG FANCM FAN1
3 DNA repair GO:0006281 9.43 USP1 FANCM FANCI FANCD2 FAN1 ATR
4 response to gamma radiation GO:0010332 9.32 POLG FANCD2
5 interstrand cross-link repair GO:0036297 9.1 USP1 FANCM FANCI FANCD2 FAN1 ATR

Molecular functions related to Fanconi Anemia, Complementation Group I according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.43 POLG H2AC18 FANCM FANCI FAN1 ATR
2 DNA polymerase binding GO:0070182 8.62 FANCI FANCD2

Sources for Fanconi Anemia, Complementation Group I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....